ASCO

218326-thumb
Oral Abstract Session
KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer
Meeting: 2023 ASCO Annual Meeting
Date: June 3, 2023
220035-thumb
Oral Abstract Session
Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: DESTINY-PanTumor02 (DP-02) interim results
Meeting: 2023 ASCO Annual Meeting
Date: June 5, 2023
223017-thumb
Poster Session
A confirmatory trial of modified radical hysterectomy for patients with FIGO stage IB1 cervical cancer with tumor diameter preoperatively estimated at 2 cm or less: Japan Clinical Oncology Group study, JCOG1101
Meeting: 2023 ASCO Annual Meeting
Date: June 5, 2023
218327-thumb
Oral Abstract Session
In situ immune impact of nivolumab + ipilimumab combination before standard chemoradiation therapy (RTCT) for FIGO IB3-IVA in patients (pts) with cervical squamous carcinoma: COLIBRI trial, a GINECO study
Meeting: 2023 ASCO Annual Meeting
Date: June 3, 2023
222781-thumb
Poster Discussion Session
Expanding Options in Immunotherapy for Gynecologic Cancers
Meeting: 2023 ASCO Annual Meeting
Date: June 5, 2023
220287-thumb
Oral Abstract Session
Cervical Cancer: Not Immune to Benefit?
Meeting: 2023 ASCO Annual Meeting
Date: June 3, 2023
221789-thumb
Poster Discussion Session
Efficacy and final safety analysis of pre- and co-administration of nivolumab (Nivo) with concurrent chemoradiation (CCRT) followed by Nivo maintenance therapy in patients (pts) with locally advanced cervical carcinoma (LACvCa): Results from the phase I trial, GOTIC-018
Meeting: 2023 ASCO Annual Meeting
Date: June 5, 2023
218546-thumb
Poster Session
Phase 2 study of ISA101b (peltopepimut-S) and cemiplimab in patients with advanced HPV16+ oropharyngeal cancer who failed anti-PD1 therapy
Meeting: 2023 ASCO Annual Meeting
Date: June 5, 2023
220048-thumb
Oral Abstract Session
Durvalumab with paclitaxel/carboplatin (PC) and bevacizumab (bev), followed by maintenance durvalumab, bev, and olaparib in patients (pts) with newly diagnosed advanced ovarian cancer (AOC) without a tumor BRCA1/2 mutation (non-tBRCAm): Results from the randomized, placebo (pbo)-controlled phase III DUO-O trial
Meeting: 2023 ASCO Annual Meeting
Date: June 3, 2023
218324-thumb
Oral Abstract Session
Dostarlimab for primary advanced or recurrent (A/R) endometrial cancer (EC): Outcomes by blinded independent central review (BICR) of the RUBY trial (ENGOT-EN6-NSGO/GOG-3031/RUBY)
Meeting: 2023 ASCO Annual Meeting
Date: June 3, 2023
201819-cover
Poster Session
Characteristics, treatment patterns, and economic burden of patients with metastatic cervical cancer receiving systemic anticancer therapy
Meeting: 2021 ASCO Quality Care Symposium
Date: September 24, 2021
213787-cover
Clinical Science Symposium
Expressing Better Outcomes for Immunotherapy
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
206862-cover
Oral Abstract Session
Tisotumab vedotin (TV) + pembrolizumab (pembro) in first-line (1L) recurrent or metastatic cervical cancer (r/mCC): Interim results of ENGOT Cx8/GOG 3024/innovaTV 205
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
2013710-cover
Poster Discussion Session
What’s Next? Treatment Choices After Anti–PD-1 Antibody
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
212747-cover
Poster Session
Factors associated with acute kidney injury among patients with cancer treated with immune checkpoint inhibitor therapy: A population-based study
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
207744-cover
Poster Session
Staging locally advanced cervical cancer with FIGO 2018 versus FIGO 2008: Impact on overall survival and progression-free survival in the OUTBACK trial (ANZGOG 0902, RTOG 1174, NRG 0274)
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
207642-cover
Poster Session
Immunological correlatives of durable responses and survival benefit for patients with cervical cancer in a trial of combined chemotherapy and immune therapy
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
209729-cover
Poster Session
Factors associated with receipt of second-line recurrent or metastatic cervical cancer treatment in the United States: A retrospective administrative claims analysis
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB)
Clinical Science Symposium
Identifying gut microbial signatures associated with B cells and tertiary lymphoid structures (TLS) in the tumor microenvironment (TME) in response to immune checkpoint blockade (ICB)
Meeting: 2022 ASCO Annual Meeting
Date: June 5, 2022
Global Perspective on HPV-Related Issues
Special Sessions
Global Perspective on HPV-Related Issues
Meeting: 2022 ASCO Annual Meeting
Date: September 8, 2022
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826
Oral Abstract Session
Pembrolizumab + chemotherapy in patients with persistent, recurrent, or metastatic cervical cancer: Subgroup analysis of KEYNOTE-826
Meeting: 2022 ASCO Annual Meeting
Date: June 6, 2022
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway
Poster Session
Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway
Meeting: 2021 ASCO Annual Meeting
Date: June 5, 2021
Strategies to Harness the Immune System to Treat Cervical Cancer
Clinical Science Symposium
Strategies to Harness the Immune System to Treat Cervical Cancer
Meeting: 2021 ASCO Annual Meeting
Date: June 5, 2021
Cervical Cancer Management in the United States: Challenges and Next Steps
Education Session
Cervical Cancer Management in the United States: Challenges and Next Steps
Meeting: 2021 ASCO Annual Meeting
Date: June 4, 2021
Advances in Radiation Oncology
Education Session
Advances in Radiation Oncology
Meeting: 2021 ASCO Annual Meeting
Date: June 4, 2021
The Emerging Role of Immunotherapy in the Management of Cervical Cancer
Education Session
The Emerging Role of Immunotherapy in the Management of Cervical Cancer
Meeting: 2021 ASCO Annual Meeting
Date: June 4, 2021
Understanding the Tumor Microenvironment
Education Session
Understanding the Tumor Microenvironment
Meeting: 2021 ASCO Annual Meeting
Date: June 5, 2021
Neoantigen Landscape and Tumor Mutational Burden
Education Session
Neoantigen Landscape and Tumor Mutational Burden
Meeting: 2021 ASCO Annual Meeting
Date: June 5, 2021
Resistant Mechanisms and Combinations Partners: What Is New?
Education Session
Resistant Mechanisms and Combinations Partners: What Is New?
Meeting: 2021 ASCO Annual Meeting
Date: June 5, 2021
Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).
Plenary Session
Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274)
Meeting: 2021 ASCO Annual Meeting
Date: June 6, 2021
MedEngine is provided by Springer Healthcare. Part of the Springer Nature Group.
Privacy policy
Terms & conditions
Disclaimer

Welcome. To access this content please provide the following information.

This content was selected by and is provided to you courtesy of Sanofi K.K.

Disclaimer | Privacy policy | Terms & conditions